Next Weeks Broker Price Targets For GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC was downgraded to "underweight" by analysts at Morgan Stanley.

In related news, insider Simon Dingemans purchased 1,076 shares of the firm's stock in a transaction that occurred on Thursday, October 12th. Sterneck Capital Management Llc sold 75,442 shares as the company's stock rose 5.47% with the market. Osterweis Capital Management Inc.'s holdings in GlaxoSmithKline PLC were worth $29,082,000 at the end of the most recent quarter. The institutional investor held 22,068 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $952,000, down from 97,510 at the end of the previous reported quarter. BNP Paribas downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, September 14 to "Underperform" rating. JP Morgan upgraded the shares of GSK in report on Monday, October 12 to "Neutral" rating. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Buy" rating given on Wednesday, January 27 by Bryan Garnier & Cie. Jefferies Group LLC boosted their price target on GlaxoSmithKline plc from GBX 1,800 ($23.67) to GBX 1,900 ($24.98) and gave the company a buy rating in a research note on Friday, June 16th.

Among 2 analysts covering SVG Capital Plc (LON:SVI), 2 have Buy rating, 0 Sell and 0 Hold. The 50 day moving average went up by +1.69% whereas the 200 day average was down by -1.38%. Argus Research maintained the shares of GSK in report on Friday, August 12 with "Buy" rating. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and worldwide trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/14/verition-fund-management-llc-takes-position-in-glaxosmithkline-plc-gsk.html. It is up 4.26% since October 15, 2016 and is uptrending.

The company has mean EPS estimate of 2.87 reported by 4 number of analyst for the quarter ending Current Qtr.(Sep2017).

Portrait Mode Coming Soon on The Samsung Galaxy S8's Camera
Aside from exact pricing and availability, there's not much we don't know about the Tab Active 2. The two new add-on features on the Galaxy Tab Active 2 are the S Pen and Bixby (Home and Voice).

It is trading at $41.01 a tad above the 50 day moving average of $40.35 and just a bit lower than the 200 day moving average of $41.58.

M&T Bank Corp increased Glaxosmithkline Plc (GSK) stake by 12623050% reported in 2017Q2 SEC filing. Next quarter's EPS is forecasted at $0.74 with next year's EPS anticipated to be $2.87. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company has a market cap of $99.25 billion, a price-to-earnings ratio of 39.35 and a beta of 1.03. The analysts estimated EPS for the higher end at 0.74 and lower end at 0.74 while the year ago reported earnings per share was 0. The stock has "Buy" rating by Bank of America on Wednesday, December 9.

Investors wait GlaxoSmithKline plc (ADR) (NYSE:GSK) to report on October, 25. its quarterly earnings Wall Street analysts expect $0.83 earnings per share, $0.00 or 0.00 % from last year's $0.83 same quarter earnings. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 1.4%. According to today's trading volume GlaxoSmithKline plc is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Related Articles